Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant
Public ClinicalTrials.gov record NCT02240381. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus
Study identification
- NCT ID
- NCT02240381
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Interventions
- assessment of therapy complications Procedure
- laboratory biomarker analysis Other
Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2014
- Primary completion
- Jan 7, 2019
- Completion
- Jan 7, 2019
- Last update posted
- Jul 17, 2019
2014 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02240381, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02240381 live on ClinicalTrials.gov.